NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application covering what may be the first new salts, co-crystals and polymorphs of psilocybin in history.

CEO Dr. Sam Clark stated the company believes the new forms of psilocybin “will significantly broaden access and improve the ability of researchers and developers to work with this compound to deliver new therapeutics.”

This is why Terran has also filed a Drug Master File (DMF) with the FDA. 

Clark further …

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.